Full text is available at the source.
Abstract
Semaglutide improves symptoms and physical function in heart failure with preserved ejection fraction (HFpEF) and obesity.
- Heart failure with preserved ejection fraction (HFpEF) is a condition where the heart's ability to pump blood is maintained, yet patients experience symptoms.
- Obesity is commonly associated with worsening symptoms in individuals with HFpEF.
- The role of discussing treatment options alongside routine care for HFpEF and obesity remains unclear.
Simplified